Fulvestrant
- PDF / 169,068 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 92 Downloads / 145 Views
1 S
Pulmonary embolism: case report A retrospective, observation real-world study of 303 breast cancer patients treated with fulvestrant between January 2015 and December 2018, described a woman [age not stated], who developed pulmonary embolism during treatment with fulvestrant for hormone-receptor positive, human epidermal receptor-2 negative (HR+/HER2-) advanced breast cancer. The woman, who had HR+/HER2- advanced breast cancer, started receiving treatment with IM fulvestrant 500mg injection on day 1 and day 15, and then every 28 days. She received two 5mL injections at each buttock. However, she developed grade III pulmonary embolism as fulvestrant-related adverse event [duration of treatment to reaction onset and outcome not stated]. Lei W, et al. Efficacy and safety of fulvestrant 500mg in hormone-receptor positive human epidermal receptor 2 negative advanced breast cancer: A real-world study in China. 803519347 Journal of Cancer 11: 6612-6622, No. 22, 2020. Available from: URL: http://doi.org/10.7150/jca.47960
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
